Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of New Mexico |
---|---|
Information provided by: | University of New Mexico |
ClinicalTrials.gov Identifier: | NCT00659165 |
Patients with diabetes treated with insulin often gain weight, which may deter patients from adhering to insulin treatment. Detemir is one type of long acting insulin approved by the Food and Drug Administration for use in people with diabetes. It is similar to other long acting insulins (NPH, glargine) except that it has been associated with less weight gain compared to other types of insulin. The reasons for this are still unclear. One possibility is that detemir insulin acts differently than do other insulins in affecting how diabetic patients eat meals. The purpose of this study is to determine whether appetite and calories eaten during a meal are affected by the type of insulin used to treat diabetes. This is a pilot study which means we are gathering preliminary information to determine if a larger study can be done.
Condition | Intervention |
---|---|
Diabetes Mellitus |
Drug: detemir insulin Drug: glargine insulin |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Crossover Assignment, Efficacy Study |
Official Title: | Exploration of the Weight Neutral Effects of Insulin Detemir Compared to Insulin Glargine: A Measure of Satiety and Calories Consumed in Type 1 Diabetes |
Estimated Enrollment: | 10 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | October 2008 |
Estimated Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
detemir insulin
|
Drug: detemir insulin
Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
|
2: Experimental
glargine insulin
|
Drug: glargine insulin
Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
|
Insulin detemir is a neutral, soluble long acting insulin analog with weight neutral properties. In limited studies, it has been shown to result in less weight gain in type 1 and type 2 diabetics compared with other long acting insulin formations. A possible mechanism for its weight neutrality is the fatty acid chain that may allow for improved central nervous system activity and effects on satiety. The primary objective of this study is to determine if patients with type 1 diabetes consume fewer calories when allowed to eat to satiety while treated with insulin detemir compared to insulin glargine. Secondary objectives are 1) subject responses on validated satiety scales and food diaries, 2) bioelectrical impedance analysis, 3) resting energy expenditure on indirect calorimetry/metabolic cart measurement, and 4) centrally acting mediators of satiety measured in the serum (PYY, ghrelin, leptin).
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Stephen M Mitchell, D.O. | (505) 272-4658 | smitchell@salud.unm.edu |
Contact: Mark Burge, M.D. | (505) 272-4658 | mburge@salud.unm.edu |
United States, New Mexico | |
University of New Mexico Health Sciences Center, General Clinical Research Center | Recruiting |
Albuquerque, New Mexico, United States, 87131-0001 | |
Contact: Stephen Mitchell, D.O. 505-272-4658 smitchell@salud.unm.edu |
Principal Investigator: | Mark Burge, M.D. | University of New Mexico, Department of Internal Medicine, Division of Endocrinology |
Study Director: | Stephen Mitchell, D.O. | University og New Mexico, Department of Internal Medicine, Division of Endocrinology |
Responsible Party: | University Of New Mexico, Department of Internal Medicine/Endocrinology ( Mark Burge, M.D. ) |
Study ID Numbers: | UNM HRRC # 08-043 |
Study First Received: | April 14, 2008 |
Last Updated: | April 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00659165 History of Changes |
Health Authority: | United States: Institutional Review Board |
diabetes insulin dependent diabetes diabetes mellitus detemir levemir glargine lantus insulin |
appetite satiety centrally acting mediators of satiety three factor eating questionnaire PYY ghrelin leptin |
Metabolic Diseases Autoimmune Diseases Diabetes Mellitus Endocrine System Diseases Diabetes Mellitus Type 1 Insulin Body Weight |
Insulin, Long-Acting Hypoglycemic Agents Diabetes Mellitus, Type 1 Glargine Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
Hypoglycemic Agents Autoimmune Diseases Metabolic Diseases Immune System Diseases Diabetes Mellitus, Type 1 Physiological Effects of Drugs |
Glargine Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Pharmacologic Actions Insulin |